Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas

Research output: Contribution to journalArticle

Abstract

Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.

Original languageEnglish
Pages (from-to)120-127
JournalHormones and Cancer
Volume10
Issue number2-3
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Prolactinoma
Menopause
Prolactin
Recurrence
Calcium Gluconate
Adenoma
Multivariate Analysis
cabergoline
Pharmaceutical Preparations

Keywords

  • Cabergoline
  • Dopamine agonist
  • Hyperprolactinemia
  • Menopause
  • Prolactinoma
  • Recurrence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cancer Research

Cite this

Cabergoline Withdrawal Before and After Menopause : Outcomes in Microprolactinomas. / Indirli, Rita; Ferrante, Emanuele; Sala, Elisa; Giavoli, Claudia; Mantovani, Giovanna; Arosio, Maura.

In: Hormones and Cancer, Vol. 10, No. 2-3, 01.01.2019, p. 120-127.

Research output: Contribution to journalArticle

@article{abcd1146e5dd45f79a4c57d93081f6f6,
title = "Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas",
abstract = "Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29{\%}) than in PRE ones (35/48, 73{\%}, p < 0.005, OR 0.149, 95{\%} CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.",
keywords = "Cabergoline, Dopamine agonist, Hyperprolactinemia, Menopause, Prolactinoma, Recurrence",
author = "Rita Indirli and Emanuele Ferrante and Elisa Sala and Claudia Giavoli and Giovanna Mantovani and Maura Arosio",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12672-019-00363-4",
language = "English",
volume = "10",
pages = "120--127",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "2-3",

}

TY - JOUR

T1 - Cabergoline Withdrawal Before and After Menopause

T2 - Outcomes in Microprolactinomas

AU - Indirli, Rita

AU - Ferrante, Emanuele

AU - Sala, Elisa

AU - Giavoli, Claudia

AU - Mantovani, Giovanna

AU - Arosio, Maura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.

AB - Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.

KW - Cabergoline

KW - Dopamine agonist

KW - Hyperprolactinemia

KW - Menopause

KW - Prolactinoma

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85064595546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064595546&partnerID=8YFLogxK

U2 - 10.1007/s12672-019-00363-4

DO - 10.1007/s12672-019-00363-4

M3 - Article

AN - SCOPUS:85064595546

VL - 10

SP - 120

EP - 127

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 2-3

ER -